cm8-or-cmo

CM8 or CMO?

There are many different Cetyl Myristoleate variants and related products on the market today. And there are several which, either through ignorance or unethical marketing, have contributed to extensive confusion in the nutritional and healthcare industry. There are a couple of issues that need to be clarified.

CMO is not Cetyl Myristoleate

CMO is a trademarked product that is being sold as cerasomal cis-9 cetyl myristoleate, an analog of Cetyl Myrisotelate. Ther term cerasomal (waxy body?) will NOT be found in your chemistry texts and was constructed by the manufacturer to set this product apart. The term analog is defined as a “similar” molecule. In other words, CMO contains a similar molecule, but it is not cetyl myristoleate. Analysis, performed on several occasions, using Gas Chromatography, Mass Spectrmetry, and Fleme Ionization Detection has revealed very little, if any, Cetyl Myristoleate in this product. Unfortunately, the manufacturer, as of today, has not disclosed exactlywhat his product is.

Another common mix up is that several other manufacturers started with raw materials that contained high levels of myristic acid instead of myristoleic acid. Myristic acid is the saturated analog and when esterified with cetyl aclohol it produces Cetyl Myristate, not Cetyl Myristoleate. Before the sophisticated diagnostic procedures to analyze for CM8 were developed, may of these products were analyzed using improper methods. These products are on our health store shelves and in the network marketing industry being sold as Cetyl Myristoleate, but in fact are Cetyl Myristate.

If you are looking for genuine CM8, buyer beware. Make sure you are getting exactly what you expect. Read the labels look for the term CM8 and understand the differences.
Gas Chromatography – Flame ionization Detection (GC-FID) analysis is now considered the most accurate technique for detecting Cetyl Myristoleate (CM8) levels.

The Story of CM8

dr-harry-diehlThe story of how Cetyl Myristoleate was discovered, isolated and created started in Bethesda, Maryland in 1962. It was there that a man named Dr. Harry W. Diehl was working at the National Institutes of Health, or NIH. The NIH is a division of the US Government, and is responsible for research into diseases, afflictions and vaccines. Dr. Diehl worked in the same building where arthritis research was being conducted, however, he was no expert on arthritis. His specialty was dealing with sugar synthesis. In fact, his method of sugar synthesis was even used to prepare the oral polio vaccine that was developed by Dr. Jonas Salk.But Dr. Diehl took a special interest in arthritis when a friend developed an extreme case of it. Since it was not his specialty, he turned his own research from sugar synthesis to arthritis, hoping to find something useful for his friend. He started out the way a lot of researchers might, with mice. It was already well known that there was a known toxin called mycobacterium butyricum, or Freund’s adjuvant. When injected , this toxin is known to cause animals to become arthritic.

You can only imagine Harry Diehl’s surprise, though, when mice didn’t display those symptoms when injected. No matter what he tried, Dr. Diehl could not introduce arthritis into mice. This could only mean one thing….mice were immune to the toxin, and thus were immune to arthritis. Dr. Diehl’s next objective, then, was to identify and isolate the reason for the immunity of the mice. Utilizing a process known as thin layer chromatography on methylene chloride extract from macerated mice, Diehl noticed a mysterious compound. It was a long, tedious job, working on his own in his spare time, but Diehl finally found, isolated, and identified the extract. It was cetyl myristoleate and it protected mice from arthritis.

Once identified and isolated, the last step was to re-create CM8 synthetically, so it could be available in quantity without affecting the mice population. Harry developed a way of synthesizing Cetyl Myristoleate by combining cetyl alcohol with myristoleic acid and found that the synthesized form of Cetyl Myristoleate was just as effective in providing immunity to adjuvant-induced arthritis as the naturally occurring form (extracted from mice).

Once Dr. Diehl had done that, CM8 was born!

(To learn more about Dr. Harry Diehl, visit his website HERE)

CM8 Patents

Three CM8 patents were granted by the US Patent office, which served as validation and recognition of the successful work and research of Dr. Harry Diehl.

The first was granted in 1977, and was granted for Cetyl Myristoleate, as follows:

U.S. Patent #4049824, September 20, 1977, Cetyl Myristoleate

In 1978, Dr. Diehl was granted a patent for the actual treatment of Rheumatoid Arthritis (RA):

U.S. Patent #4113881, September 12, 1978, Method of Treating Rheumatoid Arthritis

Finally, in 1996, Dr. Diehl was granted another patent, this time for the treatment of OsteoArthritis:

U.S. Patent #5569676, October 29, 1996, Method for the Treatment of Osteoarthritis

The results of Mr. Diehl’s work and patents was confirmed and published in the prestigious Trade Journal, Pharmaceutical Sciences 1994; Issue/Vol 83: pages 296-9.

By comparison, neither Glucosamine, Chondroitin, MSM, Hyaluronic Acid, Curcurmin, Resveratrol, nor any other natural remedy holds an actual US patent based on its ability to treat arthritis, joint pain, or sports related pain.

CM8 Research

About “Independent” Research Studies

The validity of Research Studies is most often gauged by who funded the study. In many if not most cases, a product pays for a study on its own products. Such a study is not considered “independent” as the Researching Company is being paid by the product manufacturer, tainting their results. As the saying so aptly goes, ‘Money Talks”, and not the study. CM8 was subjected to two (2) Independent, non-subsidized Studies, both of which supported and confirmed the findings of Dr. Harry Diehl.

Synopsis of Cetyl Myristoleate Study I

A more recent Cetyl Myristoleate study, performed by H. Siemandi, M.D., Ph.D., was published in the August / September 1997 issue of the Townsend Letter for Doctors & Patients. This Cetyl Myristoleate study was performed as a randomized, double blind, placebo parallel trial with 382 patients who had been diagnosed with degenerative joint disease (DJD or osteoarthritis), rheumatoid arthritis, and psoriatic arthritis. This group was divided into three groups for testing. The first Group A received a complex of fatty acids (90 grams) containing 12% Cetyl Myristoleate, the second Group B received the same complex of CM fatty acid esters plus glucosamine hydrochloride, sea cucumber (a sea animal commonly found in the Great Barrier Reef in Australia – related to the Starfish), and hydrolyzed cartilage, and the third Group C received a placebo. Treatment consisted of a one-month protocol. Outcome measures included a variety of patient-reported, clinical, laboratory, and radiographic assessments. The results were as follows (expressed in percent improvement):

synopsis-of-cetyl-myristoleate-study-1

 

Synopsis of Cetyl
Myristoleate Study II

A second Independent Clinical Trial, performed by the San Diego Clinic Immunological Center, entitled “Clinical Study On Cetylmyristoleate (CM8) vs Arthritis” further confirmed the findings of both Dr. Diehl and Dr. Siemandi, and quantified the dosage and conditions for successful treatment of arthritis using CM8, and identifying conditions which might inhibit its effectiveness. The complete results of this Independent Clinical Research Trial in their entirety can also be found on the Harry Diehl website, and was

CM8 Quick Fact..

The effectiveness of CM8 is built upon a basic fundamental scientific fact. Swiss Albino Mice are “immune” from the ravages of arthritis. In nature, they do not contract it at any age.

It is also already well known that there is a known toxin called mycobacterium butyricum, or Freund’s adjuvant. When injected , this toxin is known to cause animals to become art1hritic. However, when forcibly injected with this synthetic version of arthritis, (known as Freunds adjuvant), Swiss Albino mice still could not contract arthritis.

Rats, on the other hand, ARE susceptible to adjuvant-induced arthritis when injected. Through testing, it was discovered that rats who were first treated by injection of cetyl myristoleate could not subsequently contract arthritis when injected with Freunds adjuvant, making them virtually immune to arthritis, much like the Swiss Albino Mice.

This discovery was published in PubMed.gov, the official publication of the US National Library of Medicine and the National Institutes of Health

 

CM8 Quick Fact..

Similar compounds such as cetyl myristate and cetyl elaidate (the trans-isomer of cetyl oleate, proved to be virtually ineffective in the same tests

CM8 Quick Fact..

The discoverer of cetyl myritsoleate, Dr. Harry Diehl, was an expert in sugar synthesis, and it was his method of sugar synthesis that was used to prepare the oral polio vaccine that was later developed by Dr. Jonas Salk. In the 50’s, 60’s and 70’s, Polyomyrelitis was a contagious, historically devastating disease, and in 1952, nearly 60,000 cases with more than 3000 deaths were reported in the USA. By 1979, occurences of polio thru natural infection was completely eradicated and eliminated from the United States, thanks to Dr. Salk’s vaccine. In 1977, Dr. Salk received the Presidential Medal of Freedom from President Jimmy Carter.

CM8 Quick Fact..

By a strange twist of fate, Dr. Diehl contracted arthritis in his later years. Since his discovery had not yet been widely accepted by the drug companies, he mixed himself up a batch of CM8, from which he self medicated until his eventual death in 1999, at the age of 89.

CM8 Quick Fact..

Like everything else, cetyl myristoleate does not work 100% of the time. Failure to
work can be associated with failure to follow the proper dosage or dietary
recommendations, failure to take a sufficient amount of CM8, failure of the liver to
uptake and respond to the CM8, and misdiagnosis in which the condition is not
really an arthritis-type condition.

CM8 Quick Fact..

Contraindication & Toxicity studies have been performed on cetyl myristoleate
and the lack of toxicity is evident. Test results deemed CM8 a non-toxic material
in accordance with Federal Regulations. Mega-doses were given to test animals
with no ill effects. Moreover, subsequent necropsy of these test animals showed
no effects whatsoever on their internal organs.

CM8 Quick Fact..

Cetyl myristoleate exists in nature in sperm whale oil, and in a small gland in the male beaver. At this time no other sources in nature are knwon to contain CM8. While the first amounts of CM8 for experimentation were extracted from mice, Dr. Diehl quickly developed a methiod for making cetyl myristoleate in the lab by the esterification of myristoleic acid.

CM8 Quick Fact..

Since its introduction into the US marketplace in 1999, CM8 has become the fastest growing all natural anti inflammatory compound in the USA, and it continues to grow exponentially each year.